Sept 13 (Reuters) - ProMIS Neurosciences Inc PMN.TO
* ProMIS Neurosciences designates PMN330 as third, validated lead product for development in alzheimer's disease
* ProMIS Neurosciences inc - "PMN310 is on track for initiation of clinical trials in 2019."
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.